Last reviewed · How we verify
MAZ-101association
MAZ-101association is a drug that targets the PD-1/PD-L1 pathway to modulate the immune response.
MAZ-101association is a drug that targets the PD-1/PD-L1 pathway to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | MAZ-101association |
|---|---|
| Sponsor | EMS |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1/PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MAZ-101association works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 ligands on tumor cells, and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pruritus
- Pyrexia
- Arthralgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MAZ-101association CI brief — competitive landscape report
- MAZ-101association updates RSS · CI watch RSS
- EMS portfolio CI